Dan Yoo took a breath before describing what he saw when he stopped into work on a Sunday morning at the Larry C. Hardy ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on ANI Pharmaceuticals, with a price target of $124.00. The company’s shares closed yesterday at $72.17. Divan ...

MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...

Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

Vertex acquired the drug in a $4.9bn takeover of Alpine Immune Sciences in April 2024. Credit: JHVEPhoto / Shutterstock.com Vertex Pharmaceuticals will head to US regulators after its immunoglobulin A ...

These Irish pubs have kept their doors open for centuries and proudly wear their age on their walls, all while serving up delicious pints of Guinness.

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on ...